Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.
Ghesquières H, Krzisch D, Nicolas-Virelizier E, Kanoun S, Gac AC, Guidez S, Touati M, Laribi K, Morschhauser F, Bonnet C, Waultier-Rascalou A, Orsini-Piocelle F, André M, Fournier M, Morand F, Berriolo-Riedinger A, Burroni B, Damotte D, Traverse-Glehen A, Quittet P, Casasnovas O. Ghesquières H, et al. Among authors: nicolas virelizier e. Blood. 2024 Mar 14;143(11):983-995. doi: 10.1182/blood.2023021564. Blood. 2024. PMID: 37979133 Clinical Trial.
Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.
Belhabri A, Heiblig M, Morisset S, Vila L, Santana C, Nicolas-Virelizier E, Hayette S, Tigaud I, Plesa A, Labussiere-Wallet H, Sobh M, Michallet AS, Marie B, Nicolini FE, Guillermin Y, Gaëlle F, Lebras L, Rey P, Jauffret-Bertholon L, Laude MC, Sandrine L, Michallet M. Belhabri A, et al. Among authors: nicolas virelizier e. Cancer Med. 2023 Aug;12(16):16929-16944. doi: 10.1002/cam4.6322. Epub 2023 Aug 7. Cancer Med. 2023. PMID: 37548369 Free PMC article.
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.
Al Tabaa Y, Casasnovas RO, Baillet C, Bachy E, Nicolas-Virelizier E, Schiano De Colella JM, Bailly C, Kanoun S, Guidez S, Gyan E, Gressin R, Morineau N, Ysebaert L, Le Gouill S, Tilly H, Houot R, Morschhauser F, Cartron G, Herbaux C. Al Tabaa Y, et al. Among authors: nicolas virelizier e. Blood Adv. 2023 Jul 25;7(14):3735-3738. doi: 10.1182/bloodadvances.2023009911. Blood Adv. 2023. PMID: 37067945 Free PMC article. No abstract available.
Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.
Walczak P, Choquet S, Dantal J, Boutboul D, Suarez F, Baron M, Morel V, Cluzeau T, Touati M, Elias M, Bachy E, Nicolas-Virelizier E, Houot R, Venton G, Jacquet C, Moles-Moreau MP, Jardin F, Durot E, Balegroune N, Ecotiere L, Guieze R, Kamar N, Ysebaert L, Couzi L, Gonzalez H, Roulin L, Ou K, Caillard S, Zimmermann H, Trappe RU, Roos-Weil D. Walczak P, et al. Among authors: nicolas virelizier e. Haematologica. 2023 Oct 1;108(10):2814-2819. doi: 10.3324/haematol.2022.282297. Haematologica. 2023. PMID: 36891749 Free PMC article. No abstract available.
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.
Beldi-Ferchiou A, Jais JP, Ghesquieres H, Casasnovas RO, Tilly H, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Perrot A, Nicolas-Virelizier E, Salles G, Godard N, Zamali I, De Colella JS, Claudel A, Corront B, Oberic L, Briere J, Gaulard P, Thieblemont C, Delfau-Larue MH. Beldi-Ferchiou A, et al. Among authors: nicolas virelizier e. Br J Haematol. 2023 Apr;201(2):256-266. doi: 10.1111/bjh.18642. Epub 2023 Feb 6. Br J Haematol. 2023. PMID: 36740991 Clinical Trial.
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Stamatoullas A, Ghesquières H, Feugier P, André M, Le Bras F, Gac AC, Borel C, Gastinne T, Quittet P, Morschhauser F, Ribrag V, Guidez S, Nicolas-Virelizier E, Berriolo-Riedinger A, Vander Borght T, Edeline V, Brice P. Stamatoullas A, et al. Among authors: nicolas virelizier e. Leuk Lymphoma. 2022 Dec;63(13):3063-3071. doi: 10.1080/10428194.2022.2107204. Epub 2022 Aug 17. Leuk Lymphoma. 2022. PMID: 35975738 Clinical Trial.
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup. Fornecker LM, et al. Among authors: nicolas virelizier e. J Clin Oncol. 2023 Jan 10;41(2):327-335. doi: 10.1200/JCO.21.01281. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867960 Free article. Clinical Trial.
Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.
Camus V, Belot A, Oberic L, Sibon D, Ghesquières H, Thieblemont C, Fruchart C, Casasnovas O, Michot JM, Molina TJ, Bosly A, Joubert C, Haioun C, Nicolas-Virelizier E, Feugier P, Fitoussi O, Delarue R, Tilly H. Camus V, et al. Among authors: nicolas virelizier e. Blood Adv. 2022 Dec 27;6(24):6169-6179. doi: 10.1182/bloodadvances.2022007609. Blood Adv. 2022. PMID: 35737565 Free PMC article.
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Rossi C, André M, Dupuis J, Morschhauser F, Joly B, Lazarovici J, Ghesquières H, Stamatoullas A, Nicolas-Virelizier E, Feugier P, Gac AC, Moatti H, Fornecker LM, Deau B, Joubert C, Fortpied C, Raemaekers J, Federico M, Kanoun S, Meignan M, Traverse-Glehen A, Cottereau AS, Casasnova RO. Rossi C, et al. Among authors: nicolas virelizier e. Haematologica. 2022 Dec 1;107(12):2897-2904. doi: 10.3324/haematol.2021.280004. Haematologica. 2022. PMID: 35638548 Free PMC article.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, Karlin L, Perrot A, Touzeau C, Chrétien ML, Rigaudeau S, Dib M, Nicolas-Virelizier E, Escoffre-Barbe M, Belhadj K, Mariette C, Stoppa AM, Araujo C, Doyen C, Fontan J, Kolb B, Garderet L, Brechignac S, Malfuson JV, Jaccard A, Lenain P, Borel C, Hebraud B, Benbrahim O, Dorvaux V, Manier S, Augeul-Meunier K, Vekemans MC, Randriamalala E, Chaoui D, Caers J, Chaleteix C, Benboubker L, Vincent L, Glaisner S, Zunic P, Slama B, Eveillard JR, Humbrecht-Kraut C, Morel V, Mineur P, Eisenmann JC, Demarquette H, Richez V, Vignon M, Caillot D, Facon T, Moreau P, Colin AL, Olivier P, Wuilleme S, Avet-Loiseau H, Corre J, Attal M. Roussel M, et al. Among authors: nicolas virelizier e. Blood. 2022 May 5;139(18):2747-2757. doi: 10.1182/blood.2021014635. Blood. 2022. PMID: 35511184 Free article. Clinical Trial.
69 results